Lithium as a disease-modifying therapy for Parkinson’s disease: mechanisms, preclinical evidence, and clinical prospects
Abstract
lithium orotate vs. carbonate), minimizing renal and thyroid risks, and identifying responsive patient subgroups. Comparative evaluation with other experimental therapies, such as glucagon-like peptide-1 agonists and immunotherapies, highlights lithium's appeal as a cost-effective, repurposed candidate. This review synthesizes molecular and translational evidence, emphasizes research gaps such as long-term safety and standardized dosing, and aims to guide future clinical trial design and therapeutic strategies for PD.
Fields of Study & Subjects
Parkinson's Disease Mechanisms and Treatments
Bipolar Disorder and Treatment
Neurological disorders and treatments
Publication details
- Journal / source
- Clinical Parkinsonism & Related Disorders
- Publisher
- Elsevier BV
- Volume
- 14
- Pages
- 100440–100440
- Publication date
- 1 January 2026
- Language
- EN